[go: up one dir, main page]

WO2005046561A3 - Mehrschichtige arzneiform mit einer die abgabe einer modulatorischen substanz beeinflussenden matrix - Google Patents

Mehrschichtige arzneiform mit einer die abgabe einer modulatorischen substanz beeinflussenden matrix Download PDF

Info

Publication number
WO2005046561A3
WO2005046561A3 PCT/EP2004/010300 EP2004010300W WO2005046561A3 WO 2005046561 A3 WO2005046561 A3 WO 2005046561A3 EP 2004010300 W EP2004010300 W EP 2004010300W WO 2005046561 A3 WO2005046561 A3 WO 2005046561A3
Authority
WO
WIPO (PCT)
Prior art keywords
substance
optionally
matrix
dosage form
modulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/010300
Other languages
English (en)
French (fr)
Other versions
WO2005046561A2 (de
Inventor
Rosario Lizio
Hans-Ulrich Petereit
Manfred Assmus
Hema Ravishankar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roehm GmbH Darmstadt
Original Assignee
Roehm GmbH Darmstadt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roehm GmbH Darmstadt filed Critical Roehm GmbH Darmstadt
Priority to BRPI0416492-0A priority Critical patent/BRPI0416492A/pt
Priority to US10/573,019 priority patent/US20070042045A1/en
Priority to EP04765214A priority patent/EP1682094A2/de
Priority to CA002544487A priority patent/CA2544487A1/en
Priority to JP2006538672A priority patent/JP2007510677A/ja
Publication of WO2005046561A2 publication Critical patent/WO2005046561A2/de
Publication of WO2005046561A3 publication Critical patent/WO2005046561A3/de
Priority to IL175562A priority patent/IL175562A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die Erfindung betrifft eine mehrschichtige Arzneiform für die kontrollierte Wirkstofffreisetzung, enthaltend im wesentlichen a) optional einen neutralen Kern (Nonpareilles), b) eine innere Kontrollschicht, enthaltend eine modulatorisch wirkende Substanz, die in eine die Abgabe der modulatorischen Substanz beeinflussende Matrix eingebettet ist, die pharmazeutisch verwendbare - Polymere, Wachse, Harze und/oder Proteine sowie gegebenenfalls einen Wirkstoff enthält, c) eine Wirkstoffschicht, enthaltend einen pharmazeutischen Wirkstoff und gegebenenfalls eine modulatorisch wirkende Substanz, d) eine äussere Kontrollschicht, enthaltend zu mindestens 60 Gew.-% ein oder eine Mischung aus mehreren (Meth)acrylatcopolymeren, aus 98 bis 85 C1,- bis C4-Alkylestern der (Meth)acrylsäure und 2 bis 15 Gew.-% Methacrylatmonomeren mit einer quaternären Ammoniumgruppe im Alkylrest, und gegebenenfalls bis zu 40 Gew.-% weitere pharmazeutisch verwendbare Polymere, wobei die Schichten zusätzlich und in an sich bekannter Weise pharmazeutisch übliche Hilfsstoffe enthalten können.
PCT/EP2004/010300 2003-11-13 2004-09-15 Mehrschichtige arzneiform mit einer die abgabe einer modulatorischen substanz beeinflussenden matrix Ceased WO2005046561A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0416492-0A BRPI0416492A (pt) 2003-11-13 2004-09-15 forma farmacêutica multicamadas com uma matriz a qual influencia a distribuição de uma substáncia modulatória
US10/573,019 US20070042045A1 (en) 2003-11-13 2004-09-15 Multilayer dosage form comprising a matrix that influences release of a modulatory substance
EP04765214A EP1682094A2 (de) 2003-11-13 2004-09-15 Mehrschichtige arzneiform mit einer die abgabe einer modulatorischen substanz beeinflussenden matrix
CA002544487A CA2544487A1 (en) 2003-11-13 2004-09-15 Multilayer pharmaceutical form with a matrix which influences the delivery of a modulatory substance
JP2006538672A JP2007510677A (ja) 2003-11-13 2004-09-15 調節性の物質の放出に影響を及ぼすマトリックスを有する多層の剤形
IL175562A IL175562A0 (en) 2003-11-13 2006-05-11 Multilayer dosage form comprising a matrix that influences release of a modulatory substance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10353196A DE10353196A1 (de) 2003-11-13 2003-11-13 Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
DE10353196.3 2003-11-13

Publications (2)

Publication Number Publication Date
WO2005046561A2 WO2005046561A2 (de) 2005-05-26
WO2005046561A3 true WO2005046561A3 (de) 2006-03-16

Family

ID=34585091

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/010300 Ceased WO2005046561A2 (de) 2003-11-13 2004-09-15 Mehrschichtige arzneiform mit einer die abgabe einer modulatorischen substanz beeinflussenden matrix

Country Status (10)

Country Link
US (1) US20070042045A1 (de)
EP (1) EP1682094A2 (de)
JP (1) JP2007510677A (de)
KR (1) KR20060113728A (de)
CN (1) CN1863516A (de)
BR (1) BRPI0416492A (de)
CA (1) CA2544487A1 (de)
DE (1) DE10353196A1 (de)
IL (1) IL175562A0 (de)
WO (1) WO2005046561A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1299104T1 (sl) * 2000-02-08 2009-10-31 Euro Celtique Sa Oralne formulacije opioidnih agonistov, varne pred zlorabo
EP2422773A3 (de) * 2002-09-20 2012-04-18 Alpharma, Inc. Sequestriermitteluntereinheit und zugehörige Zusammensetzungen und Verfahren
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
DE102004036437A1 (de) 2004-07-27 2006-03-23 Röhm GmbH & Co. KG Multipartikuläre Arzneiform für wenig lösliche Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
DE102004059792A1 (de) * 2004-12-10 2006-06-14 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
DE102005007059A1 (de) 2005-02-15 2006-08-24 Röhm GmbH & Co. KG Teilneutralisiertes anionisches (Meth)acrylat-Copolymer
CA2601339A1 (en) * 2005-03-29 2006-10-05 Roehm Gmbh Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance
EP1863453A2 (de) * 2005-03-29 2007-12-12 Evonik Röhm GmbH Multipartikuläre darreichungsform mit tabletten mit einer substanz mit modularer wirkung auf die wirkstofffreisetzung
KR101320016B1 (ko) * 2005-12-14 2013-10-29 주식회사 대웅 안정화된 코엔자임ｑ10, 종합 비타민 및 미네랄 성분을함유하는 복합제제
DE102006006532B4 (de) 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
ES2636657T3 (es) * 2006-06-19 2017-10-06 Alpharma Pharmaceuticals Llc Composición farmacéutica
DE102006035549A1 (de) * 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
NZ579811A (en) * 2007-03-29 2012-02-24 Panacea Biotec Ltd Modified dosage forms of tacrolimus
CA2615137A1 (en) * 2007-12-17 2009-06-17 Pharmascience Inc. Single layered controlled release therapeutic system
WO2009088673A2 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
JP2011509265A (ja) * 2008-01-10 2011-03-24 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 活性物質のパルス放出が強化された、コーティングされた医薬製剤もしくはニュートラシューティカル製剤
CN101877971A (zh) * 2008-01-10 2010-11-03 赢创罗姆有限公司 具有活性物质在结肠中增强的释放的包衣药物或营养制剂
US20110070302A2 (en) * 2008-01-10 2011-03-24 Evonik Roehm Gmbh Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release
CA2735934C (en) 2008-09-05 2014-01-07 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (adhd)
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
WO2010096732A1 (en) * 2009-02-20 2010-08-26 University Of Medicine And Dentistry Of New Jersey Combination therapy to improve drug efficiency
KR101317592B1 (ko) 2009-10-28 2013-10-15 씨제이제일제당 (주) 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제
KR101137467B1 (ko) * 2009-11-02 2012-04-20 안국약품 주식회사 테오브로민 함유 서방성 정제
WO2011107855A2 (en) * 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
AU2011292170B2 (en) * 2010-08-18 2013-10-31 Intercontinental Great Brands Llc Mouth-moistening gum compositions and products containing the same
KR101220830B1 (ko) * 2010-08-18 2013-01-10 안국약품 주식회사 테오브로민의 서방성 과립제 및 그 제조방법
EP2670400A1 (de) 2011-02-02 2013-12-11 Alpharma Pharmaceuticals LLC Pharmazeutische zusammensetzung mit einem opioid-agonisten und einem sequestrierten antagonisten
AU2013217013B2 (en) 2012-02-08 2017-04-20 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
KR101659983B1 (ko) 2012-12-31 2016-09-26 주식회사 삼양바이오팜 용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
BR112020000084A2 (pt) 2017-07-07 2020-07-07 Dsm Ip Assets B.V. comprimidos compactados
EP3459528B1 (de) 2017-09-20 2022-11-23 Tillotts Pharma Ag Herstellung von festen darreichungsformen mit antikörpern durch lösungs-/suspensionsschichtung
WO2024200722A1 (en) 2023-03-28 2024-10-03 Tillotts Pharma Ag Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0122070A2 (de) * 1983-03-18 1984-10-17 Matsushita Electric Industrial Co., Ltd. Videosignalverarbeitungseinrichtung für Videobandaufzeichnungsgeräte
JPH04360826A (ja) * 1991-06-07 1992-12-14 Bayer Yakuhin Kk 放出制御製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
AU2016992A (en) * 1991-05-20 1992-12-30 Marion Laboratories, Inc. Multi-layered controlled release formulation
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
DE19845358A1 (de) * 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
DE10250543A1 (de) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0122070A2 (de) * 1983-03-18 1984-10-17 Matsushita Electric Industrial Co., Ltd. Videosignalverarbeitungseinrichtung für Videobandaufzeichnungsgeräte
JPH04360826A (ja) * 1991-06-07 1992-12-14 Bayer Yakuhin Kk 放出制御製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199304, Derwent World Patents Index; Class B04, AN 1993-032652, XP002361914 *

Also Published As

Publication number Publication date
JP2007510677A (ja) 2007-04-26
US20070042045A1 (en) 2007-02-22
BRPI0416492A (pt) 2007-03-13
IL175562A0 (en) 2008-04-13
EP1682094A2 (de) 2006-07-26
CA2544487A1 (en) 2005-05-26
KR20060113728A (ko) 2006-11-02
WO2005046561A2 (de) 2005-05-26
DE10353196A1 (de) 2005-06-16
CN1863516A (zh) 2006-11-15

Similar Documents

Publication Publication Date Title
WO2005046561A3 (de) Mehrschichtige arzneiform mit einer die abgabe einer modulatorischen substanz beeinflussenden matrix
WO2005046649A3 (de) Mehrschichtige arzneiform, enthaltend eine in bezug auf die wirkstoffreigabe modularisch wirkende substanz
WO2006102964A3 (en) Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
ATE406876T1 (de) Mehrschichtige wirkstoffhaltige arzneiformen, die einen neutralen kern sowie einen inneren und äusseren überzug aus methacrylat-copolymeren und -monomeren umfassen
WO2007006353A3 (de) Verwendung eines teilneutralisierten, anionischen (meth) acrylat-copolymers als uberzug fur die herstellung einer arzneiform mit einer wirkstofffreisetzung bei erniedrigten ph-werten
EP2153827A3 (de) Zusammensetzung zur transdermalen Abgabe von Fentanyl
WO2007081965A3 (en) Pesticide delivery system
CA2370067A1 (en) Pharmaceutical dosage forms for controlled release producing at least a timed pulse
WO2004017920A3 (en) Novel biphenyl and biphenyl-like cannabinoids
MX2018016056A (es) Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluor o-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbo nil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo.
IL180849A (en) Medicament in a multilayer form
DE59911452D1 (de) Überzogene arzneiformen mit kontrollierter wirkstoffabgabe
EP1287822A3 (de) Mesalazine enthaltende pharmazeutische Zusammensetzungen mit gesteuerter Freisetzung
DE60115203D1 (de) Beschichtete implantate
WO2005079748A3 (en) Pharmaceutical preparation for sustained release of a pharmaceutically active ingredient
CA2476520A1 (en) Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
EP1093850A3 (de) Gepackte Kolonne und Verfahren zum Behandeln einer polymerisierbaren Verbindung
TW200635963A (en) Partially neutralized anionic (meth)acrylate copolymer
EP1632508A3 (de) Neue Ethylencopolymere, diese enthaltende Zusammensetzungen und Behandlungsverfahren
CA2299423A1 (en) Taste-masked pharmaceutical composition
EP1230855A4 (de) Zubereitung vom wässrigen dispersionstyp mit verzögerter freigabe und verfahren zu ihrer herstellung
JP2003503540A5 (de)
CA2552679A1 (en) Tulobuterol adhesive patch
WO2002060417A8 (de) Lagerstabiles haft- und bindemittel für pharmazeutische anwendungen
MX2010007578A (es) Preparacion nutriceutica o farmaceutica revestida con una liberacion acelerada controlada de sustancia activa.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480029217.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004765214

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007042045

Country of ref document: US

Ref document number: 10573019

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2544487

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/005199

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 175562

Country of ref document: IL

Ref document number: 1641/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006538672

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020067011664

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004765214

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067011664

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 10573019

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0416492

Country of ref document: BR